Ranbaxy recalls two lots of amoxicillin and clavulanate suspension in the US
This article was originally published in Scrip
Executive Summary
Ranbaxy Laboratories' US subsidiary has recalled two lots of amoxicillin and clavulanate potassium for oral suspension 400mg/5ml from the US market, following complaints that the lots turned brown upon reconstitution, instead of white.